An Ex Vivo Ovulation Screening System to Develop Non-Hormonal Female Contraceptives
Yunman (Sonia) Song,Jeffrey T. Pea,Francesca E. Duncan,John Proudfoot,Pawat Pattarawat,Shuo Xiao,Jiyang Zhang,Richard Nelson
DOI: https://doi.org/10.1124/jpet.488.101237
2024-05-15
Journal of Pharmacology and Experimental Therapeutics
Abstract:ID 101237 Poster Board 488 The current female contraceptives primarily contain progestin, a synthetic sex steroid hormone of progesterone, to block ovarian follicle maturation and ovulation. However, side effects can be serious, including hormone-related cancers, stroke, depression, and obesity, which lead to non-use or discontinuation, suggesting an urgent need of novel non-hormonal female contraception. There are currently few effective research models that recapitulate hallmarks of ovarian functions and possess scalability. We previously demonstrated that a 3D hydrogel encapsulated in vitro follicle growth (eIVFG) system faithfully recapitulates key ovarian functions, including follicle maturation, ovulation, and hormone secretion. Under the support of Bill & Melinda Gates Foundation, we established the Ovarian Contraceptive Discovery Initiative (OCDI) which is a collaborative and multi-institutional program. In Project 1 of OCDI, we aimed to use eIVFG and other approaches to develop an ex vivo ovulation screening platform to identify compounds that can block follicle rupture, a key step of ovulation, without interfering with ovarian hormone secretion. Mature mouse follicles grown from eIVFG were treated with human chorionic gonadotropin (hCG) to induce ovulation ex vivo ; meanwhile, follicles were co-treated with candidate compounds at 10 μM. Ovulation outcomes were evaluated 16 hours post-hCG. Follicles with inhibited follicle rupture were cultured for 48 hours to allow for luteinization and progesterone secretion. Using this pipeline, we screened a total of 1500 compounds, including compounds targeting established ovulatory signaling and other small molecule library compounds. So far, we identified 50 compounds that effectively blocked follicle rupture without affecting hormone secretion. These hit compounds were advanced for in-depth drug development activities such as dose-response testing, structure-activity relationship, target identification, genetic validation, and in vivo validation. Through collaborating with Project 2, we further test positive hits in orthogonal phenotypic screening assays focused on other key ovulatory events, including oocyte maturation, cumulus expansion, and egg activation. Moreover, we used a closed vitrification method to cryopreserve immature follicles to establish a high-content follicle biobank, which further increases the throughput of our ex vivo ovulation screening. Taken together, we establish a robust ex vivo ovulation screening platform which enables us to screen large compound libraries to develop non-hormonal female contraceptives.
pharmacology & pharmacy